Telomerase: a potential therapeutic target for cancer

Bibliography

• DE LANGE T: Protection of mammalian telomeres. Oncogene (2002) 21:532–540.
   PubMed Web of Science ®Google Scholar
• STEWART SA, BEN-PORATH I, CAREY VJ, O'CONNOR BE HAHN WC, WEINBERG RA: Erosion of the telomeric single-strand overhang at replicative senescence. Nat. Genet. (2003) 33:492–496.
   PubMedGoogle Scholar
• •Senescence is more closely associated with G-strand overhang erosion than actual telomere length.
   Google Scholar
• GRIFFITH JD, COMEAU L, ROSENFIELD S et al: Mammalian telomeres end in a large duplex loop. Cell (1999) 97:503–514.
   PubMed Web of Science ®Google Scholar
• ••First demonstration that telomeres incells formed looped higher-order structures with in vitro experiments attributing TRF2 with loop stabilisation.
   Google Scholar
• KARLSEDER J, BROCCOLI D, DAI Y, HARDY S, DE LANGE T: p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science (1999) 283:1321–1325.
   PubMed Web of Science ®Google Scholar
• ••TRF2 is one of the main players in protection of telomeres from being recognised as DNA breaks.
   Google Scholar
• SHAY JW, WRIGHT WE: Telomerase: a target for cancer therapeutics. Cancer Cell (2002) 2:257–265.
   PubMed Web of Science ®Google Scholar
• BLACKBURN EH: Telomere states and cell fates. Nature (2000) 408:53–6.
   PubMed Web of Science ®Google Scholar
• LARRIVEE M, LEBEL C, WELLINGER RJ: The generation of proper constitutive G-tails on yeast telomeres is dependent on the MRX complex. Genes Dev. (2004) 18:1391–1396.
   PubMedGoogle Scholar
• •Evidence of how G-strand overhangs are maintained. Especially significant when considering that leading strand synthesis results in a blunt end and even telomerase-negative cells have G-strand overhangs. Also stresses the importance of a G-strand overhang in all cells.
   Google Scholar
• VON ZGLINICKI T: Oxidative stress shortens telomeres. Trends Biochein. Sci. (2002) 27:339–344.
   PubMed Web of Science ®Google Scholar
• SHAY JW, WRIGHT WE: Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis (2004) In press.
   Google Scholar
• REDDEL RR: Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett. (2003) 194:155–162.
   PubMed Web of Science ®Google Scholar
• BODNAR AG, OUELLETTE M, FROLKIS M et al.: Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 279:349–352.
   PubMed Web of Science ®Google Scholar
• ••Exogenous expression of hTERT activates telomerase and increases the lifespan of normal cells.
   Google Scholar
• COUNTER CM, MEYERSON M, EATON EN et al.: Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene (1998) 16:1217–1222.
   PubMed Web of Science ®Google Scholar
• LEE KH, RUDOLPH KL, JU YJ et al: Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc. Natl. Acad. Sci. USA (2001) 98:3381–3386.
   PubMed Web of Science ®Google Scholar
• •Telomere dysfunction changes how cells will react to other chemotherapeutic drugs.
   Google Scholar
• FLETCHER TM: Telomerase - strategies to exploit an important chemotherapeutic target. Expert Opin. Ther. Targets (2001) 5:363–378.
   PubMedGoogle Scholar
• OULTON R, HARRINGTON L: A human telomerase-associated nuclease. Mof Biol. Cell (2004) 15:3244–3256.
   PubMed Web of Science ®Google Scholar
• MELANA SM, HOLLAND JF, POGO BG: Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin. Cancer Res. (1998) 4:693–696.
   PubMed Web of Science ®Google Scholar
• MO Y, GAN Y, SONGS et al.: Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. (2003) 63:579–585.
   PubMed Web of Science ®Google Scholar
• MULTANI AS, CHANDRA J, MCCONKER J, SEN S, CABRAL TF, PATHAK S: Cell death in paclitaxel-dependent chinese hamster ovary cells is initiated by the loss of telomeric DNA repeats. Oncol. Res. (1999) 11:455–460.
   PubMedGoogle Scholar
• NAKAMURA M, ZHOU XZ, KISHI S, LU KP: Involvement of the telomeric protein Pin2/TRF1 in the regulation of the mitotic spindle. FEBS Lett. (2002) 514:193–198.
   PubMed Web of Science ®Google Scholar
• BROWN T, SIGURDSON E, ROGATKO A, BROCCOLI D: Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann. Surg. Oncol. (2003) 10:910–915.
   PubMed Web of Science ®Google Scholar
• HERBERT B, PITTS AE, BAKER SI et al.: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Nati Acad. Sci. USA (1999) 96:14276–14281.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of gradual telomereshortening and senescence or apoptosis by olligonucleotides directed against the hTERC template region. A proof of principle that drugs inhibiting the polymerase activity of telomerase will affect telomere length only in telomerase-positive cells.
   Google Scholar
• ELAYADI AN, DEMIEVILLE A, WANCEWICZ EV, MONIA BP, COREY DR: Inhibition of telomerase by 2'-0-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. (2001) 29:1683–1689.
   PubMed Web of Science ®Google Scholar
• PRUZAN R, PONGRACZ K, GIETZEN K, WALLWEBER G, GRYAZNOV S: Allosteric inhibitors of telomerase: oligonucleotide N3'- > P5' phosphoramidates. Nucleic Acids Res. (2002) 30:559–568.
   PubMedGoogle Scholar
• HERBERT BS, PONGRACZ K, SHAY JW, GRYAZNOV SM, SHEA-HERBERT B: Oligonucleotide N3'- > P5' phosphoramidates as efficient telomerase inhibitors. Oncogene (2002) 21:638–642.
   PubMed Web of Science ®Google Scholar
• SARETZKI G: Telomerase inhibition as cancer therapy. Cancer Lett. (2003) 194:209–219.
   PubMedGoogle Scholar
• ZHANG X, MAR V, ZHOU W, HARRINGTON L, ROBINSON MO: Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. (1999) 13:2388–2399.
   PubMed Web of Science ®Google Scholar
• •Dominant-negative hTERT can affect telomere capping in addition to telomere length.
   Google Scholar
• SHARMA GG, GUPTA A, WANG H et al.: hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene (2003) 22:131–146.
   PubMed Web of Science ®Google Scholar
• NATARAJAN S, CHEN Z, WANCEWICZ EV, MONIA BP, COREY DR: Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity. Oligonucleotides (2004) 14:263–273.
   PubMed Web of Science ®Google Scholar
• KRAEMER K, FUESSEL S, SCHMIDT Uet al.: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. (2003) 9:3794–3800.
   Google Scholar
• •Combination therapy of anti-hTERT antisense and topoisomerase poisons.
   Google Scholar
• FU XH, ZHANG JS, ZHANG N, ZHANG YD: Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line. World J. Gastroenterol. (2005) 11:785–790.
   PubMedGoogle Scholar
• YOKOYAMA Y, TAKAHASHI Y, SHINOHARA A et al.: Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. (1998) 58:5406–5410.
   PubMed Web of Science ®Google Scholar
• LUDWIG A, SARETZKI G, HOLM PS et al.: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. (2001) 61:3053–3061.
   PubMed Web of Science ®Google Scholar
• HORIKAWA I, BARRETT JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis (2003) 24:1167–76.
   PubMed Web of Science ®Google Scholar
• CONG YS, WRIGHT WE, SHAY JW: Human telomerase and its regulation. Microbial. Mol. Biol. Rev (2002) 66:407–425.
   PubMed Web of Science ®Google Scholar
• POMPETTI F, PILLA D, GIANCOLA R: Cancer therapy: switching off oncogenes. Bioessays (2003) 25:104–107.
   PubMedGoogle Scholar
• WU KJ, GRANDORI C, AMACKER M et al.: Direct activation of TERT transcription by c-MYC. Nat. Genet. (1999) 21:220–224.
   PubMed Web of Science ®Google Scholar
• •Activation of hTERT transcription by an oncogene.
   Google Scholar
• XU D, POPOV N, HOU M et a/.: Switch from Myc/Max to Madl/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Li. USA (2001) 98:3826–3831.
   Google Scholar
• VELDMAN T, LIU X, YUAN H, SCHLEGEL R: Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Li. USA (2003) 100:8211–8216.
   PubMed Web of Science ®Google Scholar
• KARLSSON A, GIURIATO S, TANG F, FUNG-WEIER J, LEVAN G, FELSHER DW: Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood (2003) 101:2797–2803.
   PubMedGoogle Scholar
• CORNET AM, HANON E, REITER ER et al.: Prostatic androgen repressed message-1 (PARMA) may play a role in prostatic cell immortalisation. Prostate (2003) 56:220–230.
   PubMedGoogle Scholar
• RANGAN A, FED OROFF OY, HURLEY LH: Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule. J. Biol. Chem. (2001) 276:4640–4646.
   PubMed Web of Science ®Google Scholar
• KYO S, TAKAKURA M, TAIRA T et al.: Spl cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. (2000) 28:669–677.
   PubMedGoogle Scholar
• KANZAWA T, GERMANO IM, KONDO Y, ITO H, KYO S, KONDO S: Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. BE J. Cancer (2003) 89:922–929.
   Google Scholar
• KYO S, TAKAKURA M, KANAYA T et al.: Estrogen activates telomerase. Cancer Res. (1999) 59:5917–5921.
   PubMed Web of Science ®Google Scholar
• WANG Z, KYO S, MAIDA Y et al: Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene (2002) 21:3517–3524.
   PubMed Web of Science ®Google Scholar
• MISITI S, NANNI S, FONTEMAGGI G et al.: Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol. Cell. Biol. (2000) 20:3764–3771.
   PubMed Web of Science ®Google Scholar
• WANG S, ZHU J: Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J. Biol. Chem. (2003) 278:18842–18850.
   PubMed Web of Science ®Google Scholar
• WANG S, ZHU J: The hTERT gene is embedded in a nuclease-resistant chromatin domain. J. Biol. Chem. (2004) 279:55401–55410.
   PubMedGoogle Scholar
• WARNECKE PM, BESTOR TH: Cytosine methylation and human cancer. Curr. Opia Oncol (2000) 12:68–73.
   PubMedGoogle Scholar
• LOPATINA NG, POOLE JC, SALDANHA SN et al: Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiating human teratocarcinoma cells. Biochem. Biophys. Res. Commun. (2003) 306:650–659.
   PubMedGoogle Scholar
• LIU L, SALDANHA SN, PATE MS, ANDREWS LG, TOLLEFSBOL TO: Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer (2004) 41:26–37.
   PubMedGoogle Scholar
• GUILLERET I,BENHATTAR J: Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem. Biophys. Res. Commun. (2004) 325:1037–1043.
   PubMedGoogle Scholar
• MUKAI S, KONDO Y, KOGA S, KOMATA T, BARNA BP, KONDO S: 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. (2000) 60:4461-4467.
   Google Scholar
• •One of the first demonstrations of immediate cell death caused by antisense against a telomerase component.
   Google Scholar
• YATABE N, KYO S, KONDO S et al: 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther. (2002) 9:624–630.
   PubMedGoogle Scholar
• YEO M, RHA SY, JEUNG HC et al: Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int. J. Cancer (2005) 114:484–489.
   PubMedGoogle Scholar
• WONG JM, KUSDRA L, COLLINS K: Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat. Cell. Biol. (2002) 4:731–736.
   PubMed Web of Science ®Google Scholar
• •Telomerase is released from the nucleolus during replication and DNA damage.
   Google Scholar
• NECKERS L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. (2002) 8:S55–S61.
   PubMed Web of Science ®Google Scholar
• HOLT SE, AISNER DL, BAUR J et al: Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. (1999) 13:817–826.
   PubMed Web of Science ®Google Scholar
• •Telomerase specific heat shock proteins to function efficiently.
   Google Scholar
• FORSYTHE HL, JARVIS JL, TURNER JW, ELMORE LW, HOLT SE: Stable association of hsp90 and p23, but Not hsp70, with active human telomerase. J.Biol. Chem. (2001) 276:15571–15574.
   PubMed Web of Science ®Google Scholar
• VILLA R, FOLINI M, PORTA CD et al.: Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcirrogenesis (2003) 24:851–859.
   PubMed Web of Science ®Google Scholar
• PETERSON SE, STELLWAGEN AE, DIEDE SJ et al: The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku. Nat. Genet. (2001) 27:64–67.
   PubMed Web of Science ®Google Scholar
• MORAN-JONES K, WAYMAN L, KENNEDY DD et al: hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. Nucleic Acids Res. (2005) 33:486–496.
   PubMed Web of Science ®Google Scholar
• LEI M, PODELL ER, CECH TR: Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat. Struct. Mol Biol. (2004) 11:1223–1229.
   PubMed Web of Science ®Google Scholar
• YE JZ, DONIGIAN JR, VAN OVERBEEK M et al.: TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J. Biol. Chem. (2004) 279:47264–47271.
   Google Scholar
• •Human potl exists in complexes with a variety of other telomere binding proteins suggesting a means of cross-talk between proteins within the telomere and telomerase access.
   Google Scholar
• LOAYZA D, DE LANGE T: POT1 as a terminal transducer of TRF1 telomere length control. Nature (2003) 424:1013–1018.
   PubMed Web of Science ®Google Scholar
• KELLEHER C, KURTH I, LINGNER J:Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro. Mol Cell. Biol. (2005) 25:808–818.
   PubMed Web of Science ®Google Scholar
• ARMBRUSTER BN, LINARDIC CM, VELDMAN T, BANSAL NP, DOWNIE DL, COUNTER CM: Rescue of an hTERT mutant defective in telomere elongation by fusion with hPotl. Mol. Cell. Biol. (2004) 24:3552–3561.
   PubMedGoogle Scholar
• KONDO T, OUE N, YOSHIDA K et al: Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res. (2004) 64:523–529.
   PubMedGoogle Scholar
• ZHOU XZ, LU KP: The Pin2/ TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell (2001) 107:347–359.
   PubMed Web of Science ®Google Scholar
• BANIK SS, COUNTER CM: Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. j Biol. Chem. (2004) 279:51745–1748.
   PubMedGoogle Scholar
• VAN STEENSEL B, DE LANGE T: Control of telomere length by the human telomeric protein TRF1.Nature (1997) 385:740–3.
   PubMed Web of Science ®Google Scholar
• SMITH S, GIRIAT I, SCHMITT A, DE LANGE T: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science (1998) 282:1484–1487.
   PubMed Web of Science ®Google Scholar
• •Poly(ADMribosylation of a negative-regulator of telomere length removes it from the telomere allowing for elongation by telomerase.
   Google Scholar
• SEIMIYA H, MURAMATSU Y, OHISHI T, TSURUO T: Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell (2005) 7:25–37.
   PubMed Web of Science ®Google Scholar
• •A new discovery that drugs affecting a telomere associated protein inhibit telomerase activity by allowing inhibition by another telomere binding protein.
   Google Scholar
• GELMINI S, POGGESI M, DISTANTE V et al: Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. Cancer Lett. (2004) 216:81–87.
   PubMed Web of Science ®Google Scholar
• REZLER EM, BEARSS DJ, HURLEY LH: Telomeres and telomerases as drug targets. Curl: Opin. Pharmacol. (2002) 2:415–423.
   PubMed Web of Science ®Google Scholar
• NEIDLE S, PARKINSON GN: The structure of telomeric DNA. Curr. Opin. Struct. Biol. (2003) 13:275–283.
   PubMed Web of Science ®Google Scholar
• ••The crystal structure of human telomericDNA showing that an intramolecular G-quadruplex can have a parallel-stranded configuration.
   Google Scholar
• WANG Y, PATEL DJ: Solution structure of the human telomeric repeat cllAG3(T2AG3)31 G-tetraplex. Structure (1993) 1:263–282.
   PubMed Web of Science ®Google Scholar
• ZAHLER AM, WILLIAMSON JR, CECH TR, PRESCOTT DM: Inhibition of telomerase by G-quartet DNA structures. Nature (1991) 350:718–720.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration that G-quadruplexes affect telomerase activity.
   Google Scholar
• FLETCHER TM, SUN D, SALAZAR M, HURLEY LH: Effect of DNA secondary structure on human telomerase activity. Biochemistry (1998) 37:5536–5541.
   PubMed Web of Science ®Google Scholar
• SUN D, LOPEZ-GUAJARDO CC, QUADA J, HURLEY LH, VON HOFF DD: Regulation of catalytic activity and processivity of human telomerase. Biochemistry (1999) 38:4037–4044.
   PubMed Web of Science ®Google Scholar
• CRABBE L, VERDUN RE, HAGGBLOM CI, KARLSEDER J: Defective telomere lagging strand synthesis in cells lacking WRN helicase activity. Science (2004) 306:1951–1953.
   PubMed Web of Science ®Google Scholar
• ••The first direct demonstration thatRecQ helicases are required specifically for lagging strand synthesis at human telomeres.
   Google Scholar
• HICKSON ID: RecQ helicases: caretakers of the genome. Nat. Rev Cancer (2003) 3:169–78.
   PubMedGoogle Scholar
• YANEZ G, KHAN S, LOCOVEI A, PEDROSO I, FLETCHER T: DNA structure-dependent recruitment of telomeric proteins to single-stranded/ double-stranded DNA junctions. Biochem. Biophys. Res. Commun. (2005) in press:
   Google Scholar
• MIYOSHI D, MATSUMURA S, NAKANO S, SUGIMOTO N: Duplex dissociation of telomere DNAs induced by molecular crowding. J. Am. Chem. Soc. (2004) 126:165–169.
   PubMed Web of Science ®Google Scholar
• KERWIN SM: G-Quadruplex DNA as a target for drug design. Curr. Pharm. Des. (2000) 6:441–478.
   PubMed Web of Science ®Google Scholar
• SUN D, THOMPSON B, CATHERS BE et al: Inhibition of human telomerase by a G-quadruplex-interactive compound. [Med. Chem. (1997) 40:2113–2116.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of telomerase Inhibition by a G-quadruplex ligand.
   Google Scholar
• PERRY PJ, GOWAN SM, RESZKA AP et al: 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. ./. Med. Chem. (1998) 41:3253–3260.
   PubMed Web of Science ®Google Scholar
• TANIOUS FA, JENKINS TC, NEIDLE S, WILSON WD: Substituent position dictates the intercalative DNA-binding mode for anthracene-9,10-dione antitumor drugs. Biochemistry (1992) 31: 11632-11640.
   Google Scholar
• IZBICKA E, WHEELHOUSE RT, RAYMOND E et al.: Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. (1999) 59:639–644.
   PubMed Web of Science ®Google Scholar
• FEDOROFF OY, SALAZAR M, HAN H, CHEMERIS VV, KERWIN SM, HURLEY LH: NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA.PG - 12367–74.Biochemistry (1998) 37:12367–12374.
   Google Scholar
• KERN JT, THOMAS PW, KERWIN SM: The relationship between ligand aggregation and G-quadruplex DNA selectivity in a series of 3,4,9,10-perylenetetracarboxylic acid diimides. Biochemistry (2002) 41:11379–11389.
   PubMedGoogle Scholar
• READ M, HARRISON RJ, ROMAGNOLI B et al: Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc. Natl. Acad. Sci. USA (2001) 98:4844–4849.
   PubMed Web of Science ®Google Scholar
• LI JL, HARRISON RJ, RESZKA AP et al: Inhibition of the Bloom's and Werner's syndrome helicases by G-quadruplex interacting ligands. Biochemistry (2001) 40:15194–15202.
   PubMed Web of Science ®Google Scholar
• STAVROPOULOS DJ, BRADSHAW PS, LI X et al.: The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Hum. Mol. Genet. (2002) 11:3135–3144.
   PubMed Web of Science ®Google Scholar
• INCLES CM, SCHULTES CM, KEMPSKI H, KOEHLER H, KELLAND LR, NEIDLE S: A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. Mol. Cancer Ther. (2004) 3:1201–1206.
   PubMed Web of Science ®Google Scholar
• RIOU JF, GUITTAT L, MAILLIET P et al.: Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. USA (2002) 99:2672–2677.
   PubMed Web of Science ®Google Scholar
• •The first demonstration of cellular growth Inhibition by G-quadruplex ligands that have high specificity for quadruplex DNA and very low affinity to double-stranded DNA.
   Google Scholar
• GOMEZ D, LEMARTELEUR T, LACROIX L, MAILLIET P, MERGNY JL, RIOU JF: Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nucleic Acids Res. (2004) 32:371–379.
   PubMed Web of Science ®Google Scholar
• •A G-quadruplex ligand causes exon skipping and a G-rich sequence in an intron may be responsible.
   Google Scholar
• SHIN-YA K, WIERZBA K, MATSUO K et al.: Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J. Am. Chem. Soc. (2001) 123:1262–1263.
   PubMed Web of Science ®Google Scholar
• KIM MY, VANKAYALAPATI H, SHIN-YA K, WIERZBA K, HURLEY LH: Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. I Am. Chem. Soc. (2002) 124:2098–2099.
   PubMed Web of Science ®Google Scholar
• KIM MY, GLEASON-GUZMAN M, IZBICKA E, NISHIOKA D, HURLEY LH: The Different Biological Effects of Telomestatin and TMPyP4 Can Be Attributed to Their Selectivity for Interaction with Intramolecular or Intermolecular G-Quadruplex Structures. Cancer Res. (2003) 63:3247–3256.
   PubMed Web of Science ®Google Scholar
• •Ligands stabiliizing different types of G-quadruplexes have differential effects on telomerase-postive and -negative cells.
   Google Scholar
• TAUCHI T, SHIN-YA K, SASHIDA G et al.: Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene (2003) 22:5338–5347.
   PubMed Web of Science ®Google Scholar
• SUMI M, TAUCHI T, SASHIDA G et al.: A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Oncol. (2004) 24:1481–1487.
   Google Scholar
• GOMEZ D, PATERSKI R, LEMARTELEUR T, SHIN-YA K, MERGNY JL, RIOU JF: Interaction of telomestatin with the telomeric single-strand overhang../. Biol. Chem. (2004) 279:41487–41494.
   PubMedGoogle Scholar
• VONDERHEIDE RH, ANDERSON KS, HAHN WC, BUTLER MO, SCHULTZE JL, NADLER LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. (2001) 7:3343–3348.
   PubMed Web of Science ®Google Scholar
• VONDERHEIDE RH, DOMCHEK SM, SCHULTZE JL et al.: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. (2004) 10:828–839.
   PubMed Web of Science ®Google Scholar
• BITTON RJ: Cancer vaccines: a critical review on clinical impact. Curr. Opin. Mol Ther. (2004) 6:17–26.
   PubMedGoogle Scholar
• RODRIGUEZ PC, ZEA AH, OCHOA AC: Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol. Response Modif (2003) 21:351–364.
   PubMedGoogle Scholar
• ZOU W, LUO C, ZHANG Z et al: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene (2004) 23:457–464.
   PubMed Web of Science ®Google Scholar
• WIRTH T, ZENDER L, SCHULTE B et al: A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. (2003) 63:3181–3188.
   PubMed Web of Science ®Google Scholar
• SAVAGE HE, ROSSEN RD, HERSH EM, FREEDMAN RS, BOWEN JM, PLAGER C: Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res. (1986) 46:2127–33.
   PubMedGoogle Scholar
• LAWLEY PD, PHILLIPS DH: DNA adducts from chemotherapeutic agents. Mutat Res. (1996) 355:13–40.
   PubMed Web of Science ®Google Scholar
• ESTELLER M, HERMAN JG: Generating mutations but providing chemosensitivity: the role of 06-methylguanine DNA methyltransferase in human cancer. Oncogene (2004) 23:1–8.
   PubMed Web of Science ®Google Scholar
• BRADSHAW PS, STAVROPOULOS DJ, MEYN MS: Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage. Nat. Genet. (2005) 37:193–197.
   PubMed Web of Science ®Google Scholar
• •TRF2 is an early responder to DNA damage. Recruitment does not even require its DNA binding domain. This is one of th first instances of a role of TRF2 in general DNA repair in humans.
   Google Scholar
• KLAPPER W, QIAN W, SCHULTE C, PARWARESCH R: DNA damage transiently increases TRF2 mRNA expression and telomerase activity. Leukemia (2003) 17: 2007-2015.
   Google Scholar
• PETERSON SE, STELLWAGEN AE, DIEDE SJ et al: The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku. Nature Genet. (2001) 27:64–67.
   PubMed Web of Science ®Google Scholar
• •Evidence that telomerase may be directly recruited by or recruit DNA damage proteins.
   Google Scholar
• VARLEY H, DI S, SCHERER SW, ROYLE NJ: Characterization of terminal deletions at 7q32 and 22q13.3 healed by Be novo telomere addition. Am. J. Hum. Genet. (2000) 67:610–622.
   PubMedGoogle Scholar
• RAHMAN R, LATONEN L, WIMAN KG: hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene (2005) 24:1320–1327.
   PubMed Web of Science ®Google Scholar
• EL-DALY H, KULL M, ZIMMERMANN S, PANTIC M, WALLER CF, MARTENS UM: Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.Blood (2005) 105: 1742-1749.
   Google Scholar